其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Butallylonal CAS Registry Number: 1142-70-7 丁溴比妥

CAS Name: 5-(2-Bromo-2-propenyl)-5-(1-methylpropyl)-2,4,6(1H,3H,5H)pyrimidinetrione
Additional Names: 5-(2-bromoallyl)-5-sec-butylbarbituric acid; sonbutal
Percent Composition: C 43.58%, H 4...
Literature References: Prepn: US 1739662 (1929).

Tetracaine Hydrochloride CAS Registry Number: 136-47-0 盐酸丁卡因

CAS Name: 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester monohydrochloride
Additional Names: p-butylaminobenzoyl-2-dimethylaminoethanol hydrochloride; 2-dimethylaminoethyl 4-n-butylami...
Literature References: Prepn: US 1889645 (1932); GB 815144 (1959 to Abbott). Prepn of pharmaceutical dosage forms: Shupe, US 3272700 (1966 to Sterling Drug). Mechanism of action studies: Y.-W. Leung et al., J. Infect. Dis. 136, 679 (1977). Toxicity study: Dawes, Br. J. Pharmacol. Chemother. 1, 90 (1946). Acute toxicity: B. A. Bopp et al., J. Pharm. Sci. 67, 882 (1978). Comprehensive description: M. Riaz, Anal. Profiles Drug Subs. 18, 379-411 (1989).

Secobarbital Sodium CAS Registry Number: 309-43-3 司可巴比妥钠

CAS Name: 5-(1-Methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione monosodium salt
Additional Names: sodium 5-allyl-5-(1-methylbutyl)barbiturate; 5-allyl-5-(1-methylbutyl)barbituric ac...
Literature References: Prepn: US 1954429 (1934). Comprehensive description: I. Comer, Anal. Profiles Drug Subs. 1, 343-365 (1972). Toxicity data: E. W. Schafer, Toxicol. Appl. Pharmacol. 21, 315 (1972).

Thiopental Sodium CAS Registry Number: 71-73-8 硫喷妥钠

CAS Name: 5-Ethyldihydro-5-(1-methylbutyl)-2-thioxo-4,6(1H,5H)-pyrimidinedione monosodium salt
Additional Names: 5-ethyl-5-(1-methylbutyl)-2-thiobarbituric acid sodium salt; thiomebumal sodium;...
Literature References: Prepn: US 2153729 (1939); US 2876225 (1959). Prepn of nonhygroscopic crystals: Hartop, US 3109001 (1963 to Abbott). Acute toxicity: Christensen, Lee, Toxicol. Appl. Pharmacol. 26, 495 (1973). Comprehensive description: M. J. McLeish, Anal. Profiles Drug Subs. Excip. 21, 535-572 (1992).

Methylhexaneamine CAS Registry Number: 105-41-9 1,3-二甲基戊胺

CAS Name: 4-Methyl-2-hexanamine
Additional Names: 2-amino-4-methylhexane; 1,3-dimethylamylamine
Trademarks: Forthane (Lilly)
Percent Composition: C 72.97%, H 14.87%, N 12.16%
Literature References: Prepn: US 2350318; US 2386273 (1944, 1945 both to Lilly).

Noxythiolin CAS Registry Number: 15599-39-0 诺昔硫脲

CAS Name: N-(Hydroxymethyl)-N'-methylthiourea
Additional Names: 1-(hydroxymethyl)-3-methyl-2-thiourea; noxytiolin
Trademarks: Noxyflex-S (Geistlich)
Percent Composition: C 29.98%, H 6.71%...
Literature References: Prepn: A. Aebi, E. Hafstetter, GB 970414 (1964 to Ed. Geistlich Söhne), C.A. 61, 15981e (1964). Antibacterial activity in vitro: D. Horsfield, Clin. Trials J. 4, 625 (1967); J. I. Blenkharn, J. Pharm. Pharmacol. 42, 589 (1990). Inhibition of bacterial adherence in vitro: S. P. Gorman et al., J. Appl. Bacteriol. 60, 311 (1986). Clinical evaluation in peritonitis: F. Antos, Clin. Trials J. 17, 159 (1980); in urinary tract sepsis: M. A. Jones, A. Hasan, Br. J. Urol. 62, 311 (1988).

Aminacrine CAS Registry Number: 90-45-9 9-氨基吖啶

CAS Name: 9-Acridinamine
Additional Names: 5-aminoacridine; 9-aminoacridine
Percent Composition: C 80.39%, H 5.19%, N 14.42%
Literature References: Prepn: A. Albert, B. Ritchie, Org. Synth. coll. vol. III, 53 (1955). Toxicity study: D. C. Brodie, E. Lowenhaupt, J. Am. Pharm. Assoc. 38, 498 (1949). Spectrophotometric determn in pharmaceuticals: E. A. Bunch, J. Assoc. Off. Anal. Chem. 66, 140 (1983). DNA intercalator used to induce exptl frameshift mutations: M. Conrad, M. D. Topal, J. Biol. Chem. 261, 16226 (1986).

Floctafenine CAS Registry Number: 23779-99-9 夫洛非宁

CAS Name: 2-[[8-(Trifluoromethyl)-4-quinolinyl]amino]benzoic acid 2,3-dihydroxypropyl ester
Additional Names: N-[8-(trifluoromethyl)-4-quinolyl]anthranilic acid 2,3-dihydroxypropyl ester; 4-[o-...
Literature References: Prepn: A. Allais, J. Meier, DE 1815467; eidem, US 3644368 (1969, 1972, both to Roussel-UCLAF); G. Mouzin et al., Synthesis 1980, 54. Analgesic activity: Allais et al., Chim. Ther. 8, 154 (1973); M. Peterfalvi et al., Arch. Int. Pharmacodyn. Ther. 216, 97 (1975). Clinical investigation: Stenport, Curr. Ther. Res. 18, 303 (1975). Toxicology: R. Glomot et al., Toxicol. Appl. Pharmacol. 36, 173 (1976). Metabolism: R. K. Lynn et al., J. Clin. Pharmacol. 19, 20 (1979).

Methyl Methanesulfonate CAS Registry Number: 66-27-3 甲基磺酸甲酯

CAS Name: Methanesulfonic acid methyl ester
Additional Names: methyl methanesulfonic acid; as-dimethyl sulfite; methyl mesylate; MMS
Percent Composition: C 21.81%, H 5.49%, O 43.58%, S 29.12...
Literature References: Prepn: A. Arbusow, P. Pischtschimuka, Chem. Zentralbl. II, 685 (1909); W. E. Bissenger et al., J. Am. Chem. Soc. 70, 3940 (1948). Metabolism: E. A. Barnsley, Biochem. J. 106, 18p (1968). Mutagenicity studies: U. H. Ehling et al., Mutat. Res. 5, 417 (1968); J. Moutschen, ibid. 8, 581 (1969). Review of carcinogenicity studies: IARC Monographs 7, 253-260 (1974). Review of comparative mutagenicity of MMS and ethyl methanesulfonate, q.v.: S. Kondo, Environ. Sci. Res. 24, 743-785 (1981).

Metofoline CAS Registry Number: 2154-02-1 甲氧夫啉

CAS Name: 1-(p-Chlorophenethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinoline
Additional Names: 1-(p-chlorophenethyl)-2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline; methopholine...
Literature References: Prepn: A. Brossi et al., Helv. Chim. Acta 43, 1459 (1960); H. Besendorf et al., US 3067203 (1962 to Hoffmann-La Roche). Metabolism: G. Sciorelli, Experientia 23, 934 (1967). Review of pharmacology, toxicity and clinical experience: A. Brossi et al., in Analgetics: Medicinal Chemistry Series of Monographs vol. 5, G. deStevens, Ed. (Academic Press, New York, 1965) p 281-330.